Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association: Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010))
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Clinical Lipidology |
| Vol/bind | 16 |
| Udgave nummer | 5 |
| Sider (fra-til) | e77-e95 |
| ISSN | 1933-2874 |
| DOI |
|
| Status | Udgivet - 1 sep. 2022 |
Bibliografisk note
Funding Information:
The authors would like to acknowledge Vivian Grifantini, Luke Hamilton, and Dena Hanson for their assistance in preparing and editing this manuscript. A special thanks to Dr. Patrick Moriarty, who provided insightful comments and thoughtful suggestions during manuscript development. There was no funding for the study. Authors’ contribution: All authors contributed to this scientific statement, drafting, and revising it critically for important intellectual content, and have approved the final version. D.P.W. discloses that, in the past 12 months, he has received speaking honorarium from Osler Institute, has received research grants from Merck Sharp & Dohme and Novo Nordisk, and has participated on the advisory board for Alexion Pharmaceuticals. T.A.J. discloses that, in the past 12 months, he has received consulting fees from Amarin, Amgen, AstraZeneca, Esperion, Sanofi Regeneron, and Novartis. P.H.J. discloses that, in the past 12 months, he has received advisory board honorarium from Amgen, Sanofi Regeneron, and AstraZeneca. M.L.K. discloses that, in the past 12 months, she has received speaker and consulting honorarium from Eli Lilly, speaker honorarium from Pfizer, consulting honorarium from Amgen, and independent contractor fees from Pfizer, Eli Lilly, CardioVax, and Ionis. C.J.M. discloses that, in the past 12 months, she has nothing to disclose. B.G.N. discloses that, in the past 12 months, he has received consulting honorarium from Akcea, Amgen, Regeneron, Sanofi, and Kowa. C.E.O. discloses that, in the past 12 months, he has nothing to disclose.
Publisher Copyright:
© 2022 National Lipid Association
ID: 346781700